Syon Capital’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.08M Buy
7,554
+334
+5% +$50.7K 0.04% 500
2026
Q2
$1.13M Buy
7,220
+2,571
+55% +$385K 0.05% 305
2026
Q1
$710K Buy
4,649
+18
+0.4% +$2.76K 0.04% 425
2025
Q4
$638K Buy
4,631
+285
+7% +$37.3K 0.03% 471
2025
Q3
$557K Buy
4,346
+2,433
+127% +$297K 0.03% 460
2025
Q2
$231K Buy
+1,913
New +$216K 0.02% 645
2024
Q4
– Sell
-56,294
Closed -$6.47M – 591
2024
Q3
$6.47M Sell
56,294
-2,070
-4% -$235K 0.57% 35
2024
Q2
$6.21M Sell
58,364
-277
-0.5% -$27.8K 0.57% 35
2024
Q1
$5.67M Buy
58,641
+2,992
+5% +$307K 0.54% 37
2023
Q4
$5.62M Sell
55,649
-8,833
-14% -$853K 0.58% 32
2023
Q3
$6.57M Buy
+64,482
New +$6.55M 0.82% 23

Other funds holding NVS

Syon Capital's NVS Position: Q3 2026 in Review

Syon Capital increased its Novartis (NVS) stake by 4.6% in Q3 2026, buying an estimated $50.7K and bringing the position to 7,554 shares worth $1.08M. The position accounts for 0.04% of the portfolio, ranked #500.

Syon Capital first reported a position in NVS in Q3 2023 and has held it in 11 quarters since. The position peaked at $6.57M in Q3 2023. 1,561 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Syon Capital held 7,554 shares of Novartis worth $1.08M as of Q3 2026.
  • Syon Capital bought 334 Novartis shares in Q3 2026, an estimated $50.7K.
  • Novartis made up 0.04% of Syon Capital's portfolio in Q3 2026, its #500 holding.
  • Syon Capital first reported a position in Novartis in Q3 2023 and has held it in 11 quarters since.
  • Syon Capital's Novartis position peaked at $6.57M in Q3 2023.
  • 1,561 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Syon Capital's 13F filing for Q3 2026, filed 16 Nov 2026.